© 1998 by Oxford University Press
Journal of the National Cancer Institute, Vol. 90, No. 18, 1346-1360,
September , 1998
©Copyright 1998 Oxford University Press
ARTICLES |
erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
Affiliations of authors: A. D. Thor, S. Edgerton, Evanston Hospital and Northwestern University, Evanston, IL; D. A. Berry, C. Cirrincione, Cancer and Leukemia Group B Statistical Office, Durham, NC; D. R. Budman, North Shore University Hospital, Manhasset, NY; H. B. Muss, Vermont Cancer Center, Burlington; T. Kute, Bowman Gray School of Medicine, Winston-Salem, NC; I. C. Henderson, University of California, San Francisco; M. Barcos, Roswell Park Cancer Center, Buffalo, NY; C. Allred, University of Texas at San Antonio; L. Norton, Memorial Sloan-Kettering Cancer Center, New York, NY; E. T. Liu, University of North Carolina at Chapel Hill.
Present address: E. T. Liu, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Abstract
Background: We have previously reported that high expression of the erbB-2 gene (also known as HER-2/neu and ERBB2) in breast cancer is associated with patient response to dose-intensive treatment with cyclophosphamide, doxorubicin (Adriamycin), and 5-flurouracil (CAF) on the basis of short-term follow-up of 397 patients (set A) with axillary lymph node-positive tumors who were enrolled in Cancer and Leukemia Group B (CALGB) protocol 8541. Methods: To validate those findings, we conducted immunohistochemical analyses of erbB-2 and p53 protein expression in an additional cohort of 595 patients (set B) from CALGB 8541, as well as a molecular analysis of erbB-2 gene amplification in tumors from all patients (sets A and B). Marker data were compared with clinical, histologic, treatment, and outcome data. Results: Updated analyses of data from set A (median follow-up, 10.4 years) showed an even stronger interaction between erbB-2 expression and CAF dose, by use of either immunohistochemical or molecular data. A similar interaction between erbB-2 expression and CAF dose was observed in all 992 patients, analyzed as a single group. However, for set B alone (median follow-up, 8.2 years), results varied with the method of statistical analysis. By use of a proportional hazards model, the erbB-2 expression–CAF dose interaction was not significant for all patients. However, in the subgroups of patients randomly assigned to the high- or the moderate-dose arms, significance was achieved. When patient data were adjusted for differences by use of a prognostic index (to balance an apparent failure of randomization in the low-dose arm), the erbB-2 expression–CAF dose interaction was significant in all patients from the validation set B as well. An interaction was also observed between p53 immunopositivity and CAF dose. Conclusions: The hypothesis that patients whose breast tumors exhibit high erbB-2 expression benefit from dose-intensive CAF should be further validated before clinical implementation. Interactions between erbB-2 expression, p53 expression, and CAF dose underscore the complexities of predictive markers where multiple interactions may confound the outcome. [J Natl Cancer Inst 1998;90:1346–60]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. N. Harris, G. Broadwater, M. Abu-Khalaf, D. Cowan, A. D. Thor, D. Budman, C. T. Cirrincione, D. A. Berry, E. P. Winer, C. A. Hudis, et al. Topoisomerase II{alpha} Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013 J. Clin. Oncol., July 20, 2009; 27(21): 3430 - 3436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Liedtke, K. Broglio, S. Moulder, L. Hsu, S.-W. Kau, W. F. Symmans, C. Albarracin, F. Meric-Bernstam, W. Woodward, R. L. Theriault, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer Ann. Onc., July 12, 2009; (2009) mdp263v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Guarneri, F. Piacentini, G. Ficarra, A. Frassoldati, R. D'Amico, S. Giovannelli, A. Maiorana, G. Jovic, and P. Conte A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy Ann. Onc., July 1, 2009; 20(7): 1193 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Hassett and J. J. Griggs Disparities in Breast Cancer Adjuvant Chemotherapy: Moving Beyond Yes or No J. Clin. Oncol., May 1, 2009; 27(13): 2120 - 2121. [Full Text] [PDF]
|
|
|
|
|
|
M. P. DiGiovanna, D. F. Stern, S. Edgerton, G. Broadwater, L. G. Dressler, D. R. Budman, I. C. Henderson, L. Norton, E. T. Liu, H. B. Muss, et al. Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B J. Clin. Oncol., May 10, 2008; 26(14): 2364 - 2372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gluz, U. A. Nitz, N. Harbeck, E. Ting, R. Kates, A. Herr, W. Lindemann, C. Jackisch, W. E. Berdel, H. Kirchner, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial Ann. Onc., May 1, 2008; 19(5): 861 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Pusztai Current Status of Prognostic Profiling in Breast Cancer Oncologist, April 1, 2008; 13(4): 350 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. I. Pritchard, H. Messersmith, L. Elavathil, M. Trudeau, F. O'Malley, and B. Dhesy-Thind HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy J. Clin. Oncol., February 10, 2008; 26(5): 736 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Hofmann, O Stoss, T Gaiser, H Kneitz, P Heinmoller, T Gutjahr, M Kaufmann, T Henkel, and J Ruschoff Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy J. Clin. Pathol., January 1, 2008; 61(1): 89 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Meslin, R. Conforti, C. Mazouni, N. Morel, G. Tomasic, F. Drusch, M. Yacoub, J. C. Sabourin, J. Grassi, S. Delaloge, et al. Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer Ann. Onc., November 1, 2007; 18(11): 1793 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Hayes, A. D. Thor, L. G. Dressler, D. Weaver, S. Edgerton, D. Cowan, G. Broadwater, L. J. Goldstein, S. Martino, J. N. Ingle, et al. HER2 and Response to Paclitaxel in Node-Positive Breast Cancer N. Engl. J. Med., October 11, 2007; 357(15): 1496 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Portera and S. M. Swain The Heart of the Matter J. Clin. Oncol., September 1, 2007; 25(25): 3794 - 3796. [Full Text] [PDF]
|
|
|
|
|
|
A. C. Wolff, M. E. H. Hammond, J. N. Schwartz, K. L. Hagerty, D. C. Allred, R. J. Cote, M. Dowsett, P. L. Fitzgibbons, W. M. Hanna, A. Langer, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer J. Clin. Oncol., January 1, 2007; 25(1): 118 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Porter, W. E. Barlow, I-T. Yeh, M. G. Lin, X. P. Yuan, E. Donato, G. W. Sledge, C. L. Shapiro, J. N. Ingle, C. M. Haskell, et al. p27Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant Chemotherapy J Natl Cancer Inst, December 6, 2006; 98(23): 1723 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V Malamou-Mitsi, H Gogas, U Dafni, A Bourli, T Fillipidis, M Sotiropoulou, D Vlachodimitropoulos, S Papadopoulos, O Tzaida, G Kafiri, et al. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy Ann. Onc., October 1, 2006; 17(10): 1504 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Perez, V. J. Suman, N. E. Davidson, S. Martino, P. A. Kaufman, W. L. Lingle, P. J. Flynn, J. N. Ingle, D. Visscher, and R. B. Jenkins HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial J. Clin. Oncol., July 1, 2006; 24(19): 3032 - 3038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tanner, J. Isola, T. Wiklund, B. Erikstein, P. Kellokumpu-Lehtinen, P. Malmstrom, N. Wilking, J. Nilsson, and J. Bergh Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401 J. Clin. Oncol., June 1, 2006; 24(16): 2428 - 2436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. U. Buzdar Topoisomerase II{alpha} Gene Amplification and Response to Anthracycline-Containing Adjuvant Chemotherapy in Breast Cancer J. Clin. Oncol., June 1, 2006; 24(16): 2409 - 2411. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Compton The cancer and leukemia group B pathology committee at 50. Clin. Cancer Res., June 1, 2006; 12(11): 3617s - 3621s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Henry and D. F. Hayes Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist, June 1, 2006; 11(6): 541 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. I. Pritchard, L. E. Shepherd, F. P. O'Malley, I. L. Andrulis, D. Tu, V. H. Bramwell, M. N. Levine, and the National Cancer Institute of Canada Clinical T HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy N. Engl. J. Med., May 18, 2006; 354(20): 2103 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hurley, P. Doliny, I. Reis, O. Silva, C. Gomez-Fernandez, P. Velez, G. Pauletti, J. E. Powell, M. D. Pegram, and D. J. Slamon Docetaxel, Cisplatin, and Trastuzumab As Primary Systemic Therapy for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced Breast Cancer J. Clin. Oncol., April 20, 2006; 24(12): 1831 - 1838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Berry, C. Cirrincione, I. C. Henderson, M. L. Citron, D. R. Budman, L. J. Goldstein, S. Martino, E. A. Perez, H. B. Muss, L. Norton, et al. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer JAMA, April 12, 2006; 295(14): 1658 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rodenhuis, M. Bontenbal, Q. G. C. M. van Hoesel, W. M. Smit, M. A. Nooij, E. E. Voest, E. van der Wall, P. Hupperets, H. van Tinteren, J. L. Peterse, et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann. Onc., April 1, 2006; 17(4): 588 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Tinari, R. Lattanzio, C. Natoli, E. Cianchetti, D. Angelucci, E. Ricevuto, C. Ficorella, P. Marchetti, S. Alberti, M. Piantelli, et al. Changes of Topoisomerase II{alpha} Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival Clin. Cancer Res., March 1, 2006; 12(5): 1501 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kroger, K. Milde-Langosch, S. Riethdorf, C. Schmoor, M. Schumacher, A. R. Zander, and T. Loning Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer Patients Clin. Cancer Res., January 1, 2006; 12(1): 159 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gluck Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin Oncologist, November 1, 2005; 10(10): 780 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Knoop, H. Knudsen, E. Balslev, B. B. Rasmussen, J. Overgaard, K. V. Nielsen, A. Schonau, K. Gunnarsdottir, K. E. Olsen, H. Mouridsen, et al. Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group J. Clin. Oncol., October 20, 2005; 23(30): 7483 - 7490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Ainsworth, J M S Bartlett, J J Going, E A Mallon, A Forsyth, J Richmond, W Angerson, A Watters, and B Dunne IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTestTM in breast carcinoma J. Clin. Pathol., October 1, 2005; 58(10): 1086 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Press, G. Sauter, L. Bernstein, I. E. Villalobos, M. Mirlacher, J.-Y. Zhou, R. Wardeh, Y.-T. Li, R. Guzman, Y. Ma, et al. Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials Clin. Cancer Res., September 15, 2005; 11(18): 6598 - 6607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Dressler, D. A. Berry, G. Broadwater, D. Cowan, K. Cox, S. Griffin, A. Miller, J. Tse, D. Novotny, D. L. Persons, et al. Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients J. Clin. Oncol., July 1, 2005; 23(19): 4287 - 4297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P J Barrett-Lee Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S125 - S133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Muss, S. Woolf, D. Berry, C. Cirrincione, R. B. Weiss, D. Budman, W. C. Wood, I. C. Henderson, C. Hudis, E. Winer, et al. Adjuvant Chemotherapy in Older and Younger Women With Lymph Node-Positive Breast Cancer JAMA, March 2, 2005; 293(9): 1073 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. DiGiovanna, D. F. Stern, S. M. Edgerton, S. G. Whalen, D. Moore II, and A. D. Thor Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients J. Clin. Oncol., February 20, 2005; 23(6): 1152 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Kennedy, J. E. Quinn, P. B. Mullan, P. G. Johnston, and D. P. Harkin The Role of BRCA1 in the Cellular Response to Chemotherapy J Natl Cancer Inst, November 17, 2004; 96(22): 1659 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bernard-Marty, F. Cardoso, and M. J. Piccart Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer Oncologist, November 1, 2004; 9(6): 617 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Durbecq, M. Paesmans, F. Cardoso, C. Desmedt, A. Di Leo, S. Chan, K. Friedrichs, T. Pinter, S. Van Belle, E. Murray, et al. Topoisomerase-II{alpha} expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel Mol. Cancer Ther., October 1, 2004; 3(10): 1207 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Konecny, C. Thomssen, H. J. Luck, M. Untch, H.-J. Wang, W. Kuhn, H. Eidtmann, A. d. Bois, S. Olbricht, D. Steinfeld, et al. HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer J Natl Cancer Inst, August 4, 2004; 96(15): 1141 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Isola, M. Tanner, A. Forsyth, T. G. Cooke, A. D. Watters, and J. M. S. Bartlett Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization Clin. Cancer Res., July 15, 2004; 10(14): 4793 - 4798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Troester, K. A. Hoadley, T. Sorlie, B.-S. Herbert, A.-L. Borresen-Dale, P. E. Lonning, J. W. Shay, W. K. Kaufmann, and C. M. Perou Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer Cancer Res., June 15, 2004; 64(12): 4218 - 4226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Park, R. S. Kerbel, G. J. Kelloff, J. C. Barrett, B. A. Chabner, D. R. Parkinson, J. Peck, R. W. Ruddon, C. C. Sigman, and D. J. Slamon Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development Clin. Cancer Res., June 1, 2004; 10(11): 3885 - 3896. [Full Text] [PDF]
|
|
|
|
|
|
H. Burris III, D. Yardley, S. Jones, G. Houston, C. Broome, D. Thompson, F. A. Greco, M. White, and J. Hainsworth Phase II Trial of Trastuzumab Followed by Weekly Paclitaxel/Carboplatin As First-Line Treatment for Patients With Metastatic Breast Cancer J. Clin. Oncol., May 1, 2004; 22(9): 1621 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Bull, H. Ozcelik, D. Pinnaduwage, M. E. Blackstein, D. A.J. Sutherland, K. I. Pritchard, A. T. Tzontcheva, S. Sidlofsky, W. M. Hanna, A. H. Qizilbash, et al. The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer J. Clin. Oncol., January 1, 2004; 22(1): 86 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rennstam, M. Ahlstedt-Soini, B. Baldetorp, P.-O. Bendahl, A. Borg, R. Karhu, M. Tanner, M. Tirkkonen, and J. Isola Patterns of Chromosomal Imbalances Defines Subgroups of Breast Cancer with Distinct Clinical Features and Prognosis. A Study of 305 Tumors by Comparative Genomic Hybridization Cancer Res., December 15, 2003; 63(24): 8861 - 8868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Britz-Cunningham and S. J. Adelstein Molecular Targeting with Radionuclides: State of the Science J. Nucl. Med., December 1, 2003; 44(12): 1945 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Mamounas NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions Clin. Med. Res., October 1, 2003; 1(4): 309 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Menard, E. Biganzoli, P. Valagussa, P. Boracchi, and A. Moliterni In Reply: J. Clin. Oncol., August 15, 2003; 21(16): 3180 - 3180. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lal, P. A. Salazar, M. Ladanyi, and B. Chen Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification J. Mol. Diagn., August 1, 2003; 5(3): 155 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Campos Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer Oncologist, August 1, 2003; 8(90002): 10 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Liu Molecular Oncodiagnostics: Where We Are and Where We Need to Go J. Clin. Oncol., June 1, 2003; 21(11): 2052 - 2055. [Full Text] [PDF]
|
|
|
|
|
|
X. Yang, S. M. Edgerton, S. D. Kosanke, T. L. Mason, K. M. Alvarez, N. Liu, R. T. Chatterton, B. Liu, Q. Wang, A. Kim, et al. Hormonal and Dietary Modulation of Mammary Carcinogenesis in Mouse Mammary Tumor Virus-c-erbB-2 Transgenic Mice Cancer Res., May 15, 2003; 63(10): 2425 - 2433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Cappelletti, S. Veneroni, D. Coradini, S. Oriana, G. Tomasic, M. Younes, and M. G. Daidone Re: Tamoxifen May Be an Effective Treatment for BRCA1-Related Breast Cancer Irrespective of Estrogen Receptor Status J Natl Cancer Inst, April 16, 2003; 95(8): 629 - 630. [Full Text] [PDF]
|
|
|
|
|
|
I. C. Henderson, D. A. Berry, G. D. Demetri, C. T. Cirrincione, L. J. Goldstein, S. Martino, J. N. Ingle, M. R. Cooper, D. F. Hayes, K. H. Tkaczuk, et al. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer J. Clin. Oncol., March 15, 2003; 21(6): 976 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. De Placido, M. De Laurentiis, C. Carlomagno, C. Gallo, F. Perrone, S. Pepe, A. Ruggiero, A. Marinelli, C. Pagliarulo, L. Panico, et al. Twenty-year Results of the Naples GUN Randomized Trial: Predictive Factors of Adjuvant Tamoxifen Efficacy in Early Breast Cancer Clin. Cancer Res., March 1, 2003; 9(3): 1039 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Moliterni, S. Menard, P. Valagussa, E. Biganzoli, P. Boracchi, A. Balsari, P. Casalini, G. Tomasic, E. Marubini, S. Pilotti, et al. HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer J. Clin. Oncol., February 1, 2003; 21(3): 458 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nahta, G. N. Hortobagyi, and F. J. Esteva Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention Oncologist, February 1, 2003; 8(1): 5 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. W. Chen, W.-C. Su, H.-R. Guo, T.-W. Chang, and W.-Y. Lee p53 and c-erbB-2 but Not bcl-2 are Predictive of Metastasis-free Survival in Breast Cancer Patients Receiving Post-mastectomy Adjuvant Radiotherapy in Taiwan Jpn. J. Clin. Oncol., September 1, 2002; 32(9): 332 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J.-Y. Zhou, and L. Bernstein Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens J. Clin. Oncol., July 15, 2002; 20(14): 3095 - 3105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Osman, E. Sherman, B. Singh, E. Venkatraman, M. Zelefsky, G. Bosl, H. Scher, J. Shah, A. Shaha, D. Kraus, et al. Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent J. Clin. Oncol., July 1, 2002; 20(13): 2980 - 2987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Zujewski "Build Quality in"--HER2 Testing in the Real World J Natl Cancer Inst, June 5, 2002; 94(11): 788 - 789. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Boasberg Medical Oncology Analysis Integr Cancer Ther, June 1, 2002; 1(2): 182 - 184. [PDF]
|
|
|
|
|
|
C. Van Poznak, L. Tan, K. S. Panageas, C. D. Arroyo, C. Hudis, L. Norton, and A. D. Seidman Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer J. Clin. Oncol., May 1, 2002; 20(9): 2319 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Schilsky, L. M. Dressler, D. Bucci, L. Monovich, S. Jewell, S. Suster, M. A. Caligiuri, P. W. Kantoff, and C. Compton Cooperative Group Tissue Banks As Research Resources: The Cancer and Leukemia Group B Tissue Repositories Clin. Cancer Res., May 1, 2002; 8(5): 943 - 948. [Full Text] [PDF]
|
|
|
|
|
|
A. Di Leo, D. Gancberg, D. Larsimont, M. Tanner, T. Jarvinen, G. Rouas, S. Dolci, J.-Y. Leroy, M. Paesmans, J. Isola, et al. HER-2 Amplification and Topoisomerase II{alpha} Gene Aberrations as Predictive Markers in Node-positive Breast Cancer Patients Randomly Treated Either with an Anthracycline-based Therapy or with Cyclophosphamide, Methotrexate, and 5-Fluorouracil Clin. Cancer Res., May 1, 2002; 8(5): 1107 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Tubbs, J. Pettay, M. Skacel, R. Powell, M. Stoler, P. Roche, and J. Hainfeld Gold-Facilitated in Situ Hybridization : A Bright-Field Autometallographic Alternative to Fluorescence in Situ Hybridization for Detection of HER-2/neu Gene Amplification Am. J. Pathol., May 1, 2002; 160(5): 1589 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Coon, E. Marcus, S. Gupta-Burt, S. Seelig, K. Jacobson, S. Chen, V. Renta, G. Fronda, and H. D. Preisler Amplification and Overexpression of Topoisomerase II{alpha} Predict Response to Anthracycline-based Therapy in Locally Advanced Breast Cancer Clin. Cancer Res., April 1, 2002; 8(4): 1061 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Park, K. Hong, D. B. Kirpotin, G. Colbern, R. Shalaby, J. Baselga, Y. Shao, U. B. Nielsen, J. D. Marks, D. Moore, et al. Anti-HER2 Immunoliposomes: Enhanced Efficacy Attributable to Targeted Delivery Clin. Cancer Res., April 1, 2002; 8(4): 1172 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Seidman, C. Hudis, M. K. Pierri, S. Shak, V. Paton, M. Ashby, M. Murphy, S. J. Stewart, and D. Keefe Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience J. Clin. Oncol., March 1, 2002; 20(5): 1215 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Guidi, D. A. Berry, G. Broadwater, B. Helmchen, I. J. Bleiweiss, D. R. Budman, I. C. Henderson, L. Norton, and D. F. Hayes Association of Angiogenesis and Disease Outcome in Node-Positive Breast Cancer Patients Treated With Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil: A Cancer and Leukemia Group B Correlative Science Study From Protocols 8541/8869 J. Clin. Oncol., February 1, 2002; 20(3): 732 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Menard, A. Balsari, P. Casalini, E. Tagliabue, M. Campiglio, R. Bufalino, and N. Cascinelli HER-2-positive Breast Carcinomas As a Particular Subset with Peculiar Clinical Behaviors Clin. Cancer Res., February 1, 2002; 8(2): 520 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 National Institutes of Health Consensus Developmen National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000 J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 5 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ravdin Is Her2 of Value in Identifying Patients Who Particularly Benefit From Anthracyclines During Adjuvant Therapy? A Qualified Yes. J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 80 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Sledge Jr. Is HER-2/neu a Predictor of Anthracycline Utility? No. J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 85 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Fornier, A. D. Seidman, M. Theodoulou, M. E. Moynahan, V. Currie, M. Moasser, N. Sklarin, T. Gilewski, G. D'Andrea, R. Salvaggio, et al. Doxorubicin Followed by Sequential Paclitaxel and Cyclophosphamide versus Concurrent Paclitaxel and Cyclophosphamide: 5-Year Results of a Phase II Randomized Trial of Adjuvant Dose-dense Chemotherapy for Women with Node-positive Breast Carcinoma Clin. Cancer Res., December 1, 2001; 7(12): 3934 - 3941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. S. Kim, S. N. Konoplev, F. Montemurro, E. Hoy, T. L. Smith, G. Rondon, R. E. Champlin, A. A. Sahin, and N. T. Ueno HER-2/neu Overexpression As a Poor Prognostic Factor for Patients with Metastatic Breast Cancer undergoing High-dose Chemotherapy with Autologous Stem Cell Transplantation Clin. Cancer Res., December 1, 2001; 7(12): 4008 - 4012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Paradiso, F. Schittulli, G. Cellamare, A. Mangia, F. Marzullo, V. Lorusso, and M. De Lena Randomized Clinical Trial of Adjuvant Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy for Patients With Fast-Proliferating, Node-Negative Breast Cancer J. Clin. Oncol., October 1, 2001; 19(19): 3929 - 3937. [Abstract] [Full Text]
|
|
|
|
|
|
W. N. Hait The Prognostic and Predictive Values of ECD-HER-2 Clin. Cancer Res., September 1, 2001; 7(9): 2601 - 2604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Hayes, H. Yamauchi, G. Broadwater, C. T. Cirrincione, S. P. Rodrigue, D. A. Berry, J. Younger, L. L. Panasci, F. Millard, D. B. Duggan, et al. Circulating HER-2/erbB-2/c-neu (HER-2) Extracellular Domain as a Prognostic Factor in Patients with Metastatic Breast Cancer: Cancer and Leukemia Group B Study 8662 Clin. Cancer Res., September 1, 2001; 7(9): 2703 - 2711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Thor Are Patterns of HER-2/neu Amplification and Expression Among Primary Tumors and Regional Metastases Indicative of Those in Distant Metastases and Predictive of Herceptin Response? J Natl Cancer Inst, August 1, 2001; 93(15): 1120 - 1121. [Full Text] [PDF]
|
|
|
|
|
|
R. Simon, A. Nocito, T. Hubscher, C. Bucher, J. Torhorst, P. Schraml, L. Bubendorf, M. M. Mihatsch, H. Moch, K. Wilber, et al. Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer J Natl Cancer Inst, August 1, 2001; 93(15): 1141 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhang, P. M. Laborde, K. R. Coombes, D. A. Berry, and S. R. Hamilton Cancer Genomics: Promises and Complexities Clin. Cancer Res., August 1, 2001; 7(8): 2159 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Thor, S. M. Edgerton, S. Liu, D. H. Moore II, and D. J. Kwiatkowski Gelsolin as a Negative Prognostic Factor and Effector of Motility in erbB-2-positive Epidermal Growth Factor Receptor-positive Breast Cancers Clin. Cancer Res., August 1, 2001; 7(8): 2415 - 2424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000 J Natl Cancer Inst, July 4, 2001; 93(13): 979 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.-H. Chow, S.-H. Chan, T.-S. Tzai, C.-L. Ho, and H.-S. Liu Expression Profiles of ErbB Family Receptors and Prognosis in Primary Transitional Cell Carcinoma of the Urinary Bladder Clin. Cancer Res., July 1, 2001; 7(7): 1957 - 1962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Piccart, A. Di Leo, M. Beauduin, A. Vindevoghel, J. Michel, C. Focan, A. Tagnon, F. Ries, P. Gobert, C. Finet, et al. Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer J. Clin. Oncol., June 15, 2001; 19(12): 3103 - 3110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. N. Harris, L. Yang, V. Liotcheva, S. Pauli, J. D. Iglehart, O. M. Colvin, and T. S. Hsieh Induction of Topoisomerase II Activity after ErbB2 Activation Is Associated with a Differential Response to Breast Cancer Chemotherapy Clin. Cancer Res., June 1, 2001; 7(6): 1497 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Petit, C. Borel, J.-P. Ghnassia, J.-F. Rodier, A. Escande, R. Mors, and P. Haegele Chemotherapy Response of Breast Cancer Depends on HER-2 Status and Anthracycline Dose Intensity in the Neoadjuvant Setting Clin. Cancer Res., June 1, 2001; 7(6): 1577 - 1581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, S. M. Edgerton, D. H. Moore II, and A. D. Thor Measures of Cell Turnover (Proliferation and Apoptosis) and Their Association with Survival in Breast Cancer Clin. Cancer Res., June 1, 2001; 7(6): 1716 - 1723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins, and T.M. Grogan Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message J. Clin. Oncol., May 15, 2001; 19(10): 2714 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamauchi, V. Stearns, and D. F. Hayes When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2334 - 2356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. N. Harris, V. Liotcheva, G. Broadwater, M. J. Ramirez, P. Maimonis, S. Anderson, T. Everett, D. Harpole, M. B. Moore, D. A. Berry, et al. Comparison of Methods of Measuring HER-2 in Metastatic Breast Cancer Patients Treated With High-Dose Chemotherapy J. Clin. Oncol., March 15, 2001; 19(6): 1698 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Bast Jr, P. Ravdin, D. F. Hayes, S. Bates, H. Fritsche Jr, J. M. Jessup, N. Kemeny, G. Y. Locker, R. G. Mennel, and M. R. Somerfield 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 15, 2001; 19(6): 1865 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Eisenhauer From the Molecule to the Clinic -- Inhibiting HER2 to Treat Breast Cancer N. Engl. J. Med., March 15, 2001; 344(11): 841 - 842. [Full Text] [PDF]
|
|
|
|
|
|
S. Geisler, P. E. Lønning, T. Aas, H. Johnsen, O. Fluge, D. F. Haugen, J. R. Lillehaug, L. A. Akslen, and A.-L. Børresen-Dale Influence of TP53 Gene Alterations and c-erbB-2 Expression on the Response to Treatment with Doxorubicin in Locally Advanced Breast Cancer Cancer Res., March 1, 2001; 61(6): 2505 - 2512. [Abstract] [Full Text]
|
|
|
|
|
|
S. Menard, P. Valagussa, S. Pilotti, L. Gianni, E. Biganzoli, P. Boracchi, G. Tomasic, P. Casalini, E. Marubini, M. I. Colnaghi, et al. Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node-Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables J. Clin. Oncol., January 15, 2001; 19(2): 329 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lebeau, D. Deimling, C. Kaltz, A. Sendelhofert, A. Iff, B. Luthardt, M. Untch, and U. Lohrs HER-2/neu Analysis in Archival Tissue Samples of Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence In Situ Hybridization J. Clin. Oncol., January 15, 2001; 19(2): 354 - 363. [Abstract] [Full Text] [PDF]
|
|